Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 11 de 11 
Presentar resultados
Seleccionar todas
2.Tiene citas relacionadas Cita con resumen
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:22 de mayo. [Ref.ID 103632]
5. Cita con resumen
Anónimo. FDA to evaluate increased risk of heart -related death and death from all causes with the gout medicine febuxostat (Uloric). U.S. Food and Drug Administration 2017:15 de noviembre. [Ref.ID 102144]
7. Cita con resumen
Psaty BM, Goodman SN, Breckenridge A. Advances in regulatory science at the Food and Drug Administration. JAMA 2013;309:2103-4. [Ref.ID 95457]
8.Tiene citas relacionadas Cita con resumen
Jha AK, Classen DC. Getting moving on patient safety - Harnessing electronic data for safer care. N Engl J Med 2011;365:1756-8. [Ref.ID 91643]
9.
Qato DM, Alexander GC. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. JAMA 2011;306:1595-6. [Ref.ID 91546]
10.Tiene citas relacionadas Cita con resumen
Classen DC, Resar R, Griffin F, Federico F, Frankel T, Kimmel N, Whittington JC, Frankel A, Seger A, James BC. 'Global trigger tool' shows that adverse events in hospitals may be ten times greater than previously measured. Health Affairs 2011;30:581-9. [Ref.ID 90387]
11.
Arana A, Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation. Drug Saf 2010;33:489-501. [Ref.ID 88648]
Seleccionar todas
 
 1 a 11 de 11